vestibИзвестия Национальной академии наук Беларуси. Серия биологических наукProceedings of the National Academy of Sciences of Belarus, Biological Series1029-89402524-230XThe Republican Unitary Enterprise Publishing House "Belaruskaya Navuka"10.29235/1029-8940-2018-63-3-374-381vestib-387Research ArticleСтатьиК ВОПРОСУ О СОЗДАНИИ УНИВЕРСАЛЬНОЙ ИММУНОТЕРАПЕВТИЧЕСКОЙ ПРОТИВОРАКОВОЙ ВАКЦИНЫON THE PROBLEM OF DEVELOPMENT OF THE UNIVERSAL IMMUNOTHERAPEUTIC ANTICANCER VACCINEЗинченкоА. И.ZinchenkoA. I.

член-корреспондент, д-р биол. наук, профессор, заведующий лабораторией

Corresponding Member, D. Sc. (Biol.), Professor, Head of the Laboratory

zinch@mbio.bas-net.byЩеколоваА. С.SchokolovaA. S.

канд. биол. наук, ст. науч. сотрудник

Ph. D. (Biol.), Senior researcher

nastindeathnote@gmail.comБиричевскаяЛ. Л.BirichevskayaL. L.

канд. биол. наук, ст. науч. сотрудник

Ph. D. (Biol.), Senior researcher

l.birichevskaya@mbio.bas-net.byИнститут микробиологии НАН Беларуси, МинскInstitute of Microbiology of the National Academy of Sciences of Belarus, Minsk201825082018633374381Copyright © Зинченко А.И., Щеколова А.С., Биричевская Л.Л., 20182018Зинченко А.И., Щеколова А.С., Биричевская Л.Л.Zinchenko A.I., Schokolova A.S., Birichevskaya L.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vestibio.belnauka.by/jour/article/view/387

В этом сообщении теоретически обосновывается метод лечения опухолей путем активации in situ дендритных клеток с помощью внутриопухолевой инъекции двух молекулярных «сигналов опасности» бактериального происхождения – плазмидной ДНК, содержащей неметилированные CpG-динуклеотиды, и циклического дигуанозинмонофосфата (цикло-диГМФ). Приведенные в литературе сведения дают основания предположить, что эта процедура способна высвободить из погибающих раковых клеток большое число опухоль-ассоциированных мутантных белков, рекрутировать в ложе опухоли эффекторные иммуноциты, активировать дендритные клетки и в результате – индуцировать мощный системный антираковый Т-клеточный иммунный ответ, способный ликвидировать как первичные солидные опухоли, так и возможные метастазы.

 

The authors of this paper theoretically substantiated the cancer treatment method, using in situ activation of dendritic cells with intratumoral injection of two molecular “danger signals” of bacterial origin – plasmid DNA containing unmethylated CpG-dinucleotides and cyclic diguanosine monophosphate (cyclo-diGMP). Based on literature data it might be presumed that this procedure is capable to release from the dying cancer cells a large number of tumor-associated mutant proteins, to recruit effector immune cells into the tumor bed, to activate dendritic cells and as a result to induce a potent anti-cancer T-cellular immune response leading to elimination of both primary solid tumors and possible metastases.

 

иммунотерапия ракатерапевтическая вакцинациклический дигуанозинмонофосфатплазмидная ДНКнеметилированные CpG-динуклеотидыдендритные клеткиcancer immunotherapytherapeutic vaccinecyclic diguanosine monophosphateplasmid DNAunmethylated CpG-dinucleotidesdendritic cellsReferencesAkhmetzhanov, A. R. Dynamics of preventive vs post-diagnostic cancer control using low-impact measures / A. R. Akhmetzhanov, M. E. Hochberg // eLife. ‒ 2015. ‒ Vol. 4. ‒ Art. e06266. https://doi.org/10.7554/eLife.06266Akhmetzhanov A. R., Hochberg M. E. Dynamics of preventive vs post-diagnostic cancer control using low-impact measures. eLife, 2015, vol. 4, art. e06266. https://doi.org/10.7554/eLife.06266Welch, H. G. Overdiagnosis in cancer / H. G. Welch, W. C. Black // J. of the Nat. Cancer Inst. ‒ 2010. ‒ Vol. 102, N 9. ‒ P. 605‒613. https://doi.org/10.1093/jnci/djq099Welch H. G., Black W. C. Overdiagnosis in cancer. Journal of National Cancer Institute, 2010, vol. 102, no. 9, pp. 605‒613. https://doi.org/10.1093/jnci/djq099Combining radiotherapy with immunotherapy: the past, the present and the future / E. J. van Limbergen [et al.] // Brit. J. of Radiology. ‒ 2017. ‒ Vol. 90, N 1076. ‒ Art. 20170157. https://doi.org/10.1259/bjrVan Limbergen E. J., de Ruysscher D. K., Olivo Pimentel V., Marcus D., Berbee M., Hoeben A., Rekers N., Theys J., Yaromina A., Dubois L. J., Lambin Ph. Combining radiotherapy with immunotherapy: the past, the present and the future. British Journal of Radiology, 2017, vol. 90, no. 1076, art. 20170157. https://doi.org/10.1259/bjrCore needle biopsy of breast cancer tumors increases distant metastases in a mouse model / E. G. Mathenge [et al.] // Neoplasia. ‒ 2014. ‒ Vol. 16, N 11. ‒ P. 950–960. https://doi.org/10.1016/j.neo.2014.09.004Mathenge E. G., Dean C. A., Clements D., Vaghar-Kashani A., Photopoulos S., Coyle K. M., Giacomantonio M., Malueth B., Nunokawa A., Jordan J., Lewis J. D., Gujar S. A., Marcato P., Lee P. W. K., Giacomantonio C. A. Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model. Neoplasia, 2014, vol. 16, no. 11, pp. 950–960. https://doi.org/10.1016/j.neo.2014.09.004Therapy’s shadow: a short history of the study of resistance to cancer chemotherapy / P. Keating [et al.] // Frontiers in Pharmacology. ‒ 2013. ‒ Vol. 4. ‒ Art. 58. https://doi.org/10.3389/fphar.2013.00058Keating P., Cambrosio A., Nelson N. C., Mogoutov A., Cointet J. P. Therapy’s shadow: a short history of the study of resistance to cancer chemotherapy. Frontiers in Pharmacology, 2013, vol. 4, art. 58. https://doi.org/10.3389/fphar.2013.00058Cancer stem cell plasticity drives therapeutic resistance / M. R. Doherty [et al.] // Cancers. ‒ 2016. ‒ Vol. 8. ‒ Art. 8. https://doi.org/10.3390/cancers8010008Doherty M. R., Smigiel J. M., Junk D. J., Jackson M. W. Cancer stem cell plasticity drives therapeutic resistance. Cancers, 2016, art. 8. https://doi.org/10.3390/cancers8010008Second cancer after radiotherapy, 1981–2007 / D. Bartkowiak [et al.] // Radiotherapy and Oncology. ‒ 2012. ‒ Vol. 105, N 1. ‒ P. 122–126. https://doi.org/10.1016/j.radonc.2011.09.013Bartkowiak D., Humble N., Suhr P., Hagg J., Mair K., Polivka B., Schneider U., Bottke D., Wiegel T. Second cancer after radiotherapy, 1981–2007. Radiotherapy and Oncology, 2012, vol. 105, no. 1, pp. 122–126. https://doi.org/10.1016/j. radonc.2011.09.013Sverdlov, E. D. Multidimensional complexity of cancer. Simple solutions are needed / E. D. Sverdlov // Biochemistry. ‒ 2016. ‒ Vol. 81, N 7. ‒ P. 731–738. https://doi.org/10.1134/S0006297916070099Sverdlov E. D. Multidimensional complexity of cancer. Simple solutions are needed. Biochemistry, 2016, vol. 81, no. 7, pp. 731–738. https://doi.org/10.1134/S0006297916070099Folkman, J. Cancer without disease / J. Folkman, R. Kalluri // Nature. ‒ 2004. ‒ Vol. 427, N 6977. ‒ P. 787. https://doi. org/10.1038/427787aFolkman J., Kalluri R. Cancer without disease. Nature, 2004, vol. 427, no. 6977, pp. 787. https://doi.org/10.1038/427787aCancer mortality among recipients of solid-organ transplantation in Ontario, Canada / S. A. Acuna [et al.] // JAMA Oncology. ‒ 2016. ‒ Vol. 2, N 4. ‒ P. 463‒469. https://doi.org/10.1001/jamaoncol.2015.5137Acuna S. A., Fernande K. A., Daly C., Hicks L. K., Sutradhar R., Kim S. J., Baxter N. N. Cancer mortality among recipients of solid-organ transplantation in Ontario, Canada. JAMA Oncology, 2016, vol. 2, no. 4, pp. 463‒469. https://doi. org/10.1001/jamaoncol.2015.5137Itoh, K. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas / K. Itoh, A. B. Tilden, C. M. Balch // Cancer Res. ‒ 1986. ‒ Vol. 46, N 6. ‒ P. 3011–3017.Itoh K., Tilden A. B., Balch C. M. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Research, 1986, vol. 46, no. 6, pp. 3011–3017.Ohta, A. A metabolic immune checkpoint: adenosine in tumor microenvironment / A. Ohta // Frontiers in Immunology. ‒ 2016. ‒ Vol. 7. ‒ Art. 109. https://doi.org/10.3389/fimmu.2016.00109Ohta A. A metabolic immune checkpoint: adenosine in tumor microenvironment. Frontiers in Immunology, 2016, vol. 7, art. 109. https://doi.org/10.3389/fimmu.2016.00109Kumar, T. Spontaneous regression of thoracic malignancies / T. Kumar, N. Patel, A. Talwar // Respiratory Medicine. ‒ 2010. ‒ Vol. 104, N 10. ‒ P. 1543–1550. https://doi.org/10.1016/j.rmed.2010.04.026Kumar T., Patel N., Talwar A. Spontaneous regression of thoracic malignancies. Respiratory Medicine, 2010, vol. 104, no. 10, pp. 1543–1550. https://doi.org/10.1016/j.rmed.2010.04.026Jackson, R. Saint Peregrine, O. S. M. – the patron saint of cancer patients / R. Jackson // Canad. Med. Assoc. J. ‒ 1974. ‒ Vol. 111, N 8. ‒ P. 824–827.Jackson R. Saint Peregrine, O.S.M. – the patron saint of cancer patients. Canadien Medical Association Journal, 1974, vol. 111, no. 8, pp. 824–827.Kienle, G. S. Fever in cancer treatment: Coley’s therapy and epidemiologic observations / G. S. Kienle // Global Advances in Health and Medicine. ‒ 2012. ‒ Vol. 1, N 1. ‒ P. 92–100. https://doi.org/10.7453/gahmj.2012.1.1.016Kienle G. S. Fever in cancer treatment: Coley’s therapy and epidemiologic observations. Global Advances in Health and Medicine, 2012, vol. 1, no. 1, pp. 92–100. https://doi.org/10.7453/gahmj.2012.1.1.016Krone, B. The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies / B. Krone, K. F. Kolmel, J. M. Grange // BMC Cancer. ‒ 2014. ‒ Vol. 14, N 1. ‒ Art. 595. https://doi. org/10.1186/1471-2407-14-595Krone B., Kolmel K. F., Grange J. M. The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies. BMC Cancer, 2014, vol. 14, no. 1, art. 595. https://doi.org/10.1186/1471-2407-14-595Haro, A. S. The effect of BCG-vaccination and tuberculosis on the risk of leukaemia / A. S. Haro // Developments in Biological Standardization. ‒ 1986. ‒ Vol. 58, pt. A. ‒ P. 433–439.Haro A. S. The effect of BCG-vaccination and tuberculosis on the risk of leukaemia. Developments in Biological Standardization, 1986, vol. 58, pt. A, pp. 433–449.Tsung, K. Lessons from Coley’s toxin / K. Tsung, J. A. Norton // Surgical Oncology. ‒ 2006. ‒ Vol. 15, N 1. ‒ P. 25–28. https://doi.org/10.1016/j.suronc.2006.05.002Tsung K., Norton J. A. Lessons from Coley’s toxin. Surgical Oncology, 2006, vol. 15, no. 1, pp. 25–28. https://doi. org/10.1016/j.suronc.2006.05.002Garg, A. D. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses / A. D. Garg, P. Agostinis // Immunological Rev. ‒ 2017. ‒ Vol. 280, N 1. ‒ P. 126–148. https://doi.org/10.1111/imr.12574Garg A. D., Agostinis P. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses. Immunological Reviews, 2017, vol. 280, no. 1, pp. 126–148. https://doi.org/10.1111/imr.12574Trial watch: immunogenic cell death induction by anticancer chemotherapeutics / A. Garg [et al.] // Oncoimmunology. ‒ 2017. ‒ Vol. 6, N 12. ‒ Art. e1386829. https://doi.org/10.1080/2162402X.2017.1386829Garg A. D., More S., Rufo N., Mece O., Sassano M. L., Agostinis P., Zitvogel L., Kroemer G., Galluzzi L. Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology, 2017, vol. 6, no. 12, art. e1386829. https://doi.org/10.1080/2162402X.2017.1386829Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines / L. Vandenberk [et al.] // Frontiers in Immunology. ‒ 2016. ‒ Vol. 6. ‒ Art. 663. https://doi.org/10.3389/fimmu.2015.00663Vandenberk L., Belmans J., van Woensel M., Riva M., van Gool S. W. Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. Frontiers in Immunology, 2016, vol. 6, art. 663. https://doi.org/10.3389/fimmu.2015.00663Posey, A. D. Cancer killers / A. D. Posey, C. H. June, B. L. Levine // Scientific Amer. ‒ 2017. ‒ Vol. 316, N 3. ‒ P. 38–43. https://doi.org/10.1038/scientificamerican0317-38Posey A. D., June C. H., Levine B. L. Cancer killers. Scientific American, 2017, vol. 316, no. 3, pp. 38–43. https://doi. org/ 10.1038/scientificamerican0317-38Hammerich, L. In situ vaccination: cancer immunotherapy both personalized and off-the-shelf / L. Hammerich, A. Binder, J. D. Brody // Molecular Oncology. ‒ 2015. ‒ Vol. 9, N 10. ‒ P. 1966–1981. https://doi.org/10.1016/j.molonc.2015.10.016Hammerich L., Binder A., Brody J. D. In situ vaccination: cancer immunotherapy both personalized and off-the-shelf. Molecular Oncology, 2015, vol. 9, no. 10, pp. 1966–1981. https://doi.org/10.1016/j.molonc.2015.10.016Targeting malignant B cells as antigen-presenting cells: TLR-9 agonist induces systemic regression of lymphoma / N. Klein-González [et al.] // Expert Rev. Vaccines. ‒ 2011. ‒ Vol. 10, N 3. ‒ P. 295‒298. https://doi.org/10.1586/erv.11.6Klein-González N., Holtick U., Fairfax K., Weihrauch M. R., von Bergwelt-Baildon M. S. Targeting malignant B cells as antigen-presenting cells: TLR-9 agonist induces systemic regression of lymphoma. Expert Review of Vaccines, 2011, vol. 10, no. 3, pp. 295‒298. https://doi.org/10.1586/erv.11.6Therapeutic injection of a C-type CpG ODN induced an antitumor immune response in C57/BL6 mice of orthotopically transplanted hepatocellular carcinoma / H. Jia [et al.] // Oncology Res. ‒ 2016. ‒ Vol. 23, N 6. ‒ P. 321–326. https://doi. org/10.3727/096504016X14570992647041Jia H., Zhao T., Zou D., Jia X., Gao J., Song X. Therapeutic injection of a C-type CpG ODN induced an antitumor immune response in C57/BL6 mice of orthotopically transplanted hepatocellular carcinoma. Oncology Research, 2016, vol. 23, no. 6, pp. 321–326. https://doi.org/10.3727/096504016X14570992647041STING is a direct innate immune sensor of cyclic di-GMP / D. L. Burdette [et al.] // Nature. ‒ 2011. ‒ Vol. 478, N 7370. ‒ P. 515–518. https://doi.org/10.1038/nature10429Burdette D. L., Monroe K. M., Sotelo-Troha K., Iwig J. S., Eckert B., Hyodo M., et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature, 2011, vol. 478, no. 7370, pp. 515–518. https://doi.org/10.1038/nature10429STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer / D. Chandra [et al.] // Cancer Immunology Res. ‒ 2014. ‒ Vol. 2, N 9. ‒ P. 901–910. https://doi.org/10.1158/2326-6066.CIR-13-0123Chandra D., Quispe-Tintaya W., Jahangir A., Asafu-Adjei D., Ramos I., Sintim H. O., Zhou J., Hayakawa Y., Karaolis D. K., Gravekamp C. STING ligand c-di-GMP improves cancer vaccination against metastatic breast cancer. Cancer Immunology Research, 2014, vol. 2, no. 9, pp. 901–910. https://doi.org/10.1158/2326-6066.CIR-13-0123Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity / L. Corrales [et al.] // Cell Reports. ‒ 2015. ‒ Vol. 11, N 7. ‒ P. 1018–1030. https://doi.org/ 10.1016/j.celrep.2015.04.031Corrales L., Glickman L. H., McWhirter S. M., Kanne D. B., Sivick K. E., Katibah G. E., Woo S. R., Lemmens E., Banda T., Leong J. J., Metchette K., Dubensky T. W., Gajewski T. F. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Reports, 2015, vol. 11, no. 7, pp. 1018–1030. https://doi.org/ 10.1016/j.celrep.2015.04.031Rivera Vargas, T. Rationale for stimulator of interferon genes-targeted cancer immunotherapy / T. Rivera Vargas, I. Benoit-Lizon, L. Apetoh // European J. of Cancer. ‒ 2017. ‒ Vol. 75. ‒ P. 86–97. https://doi.org/10.1016/j.ejca.2016.12.028Rivera Vargas T., Benoit-Lizon I., Apetoh L. Rationale for stimulator of interferon genes-targeted cancer immunotherapy. European Journal of Cancer, 2017, vol. 75, pp. 86–97. https://doi.org/10.1016/j.ejca.2016.12.028Carpentier, A. F. CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma / A. F. Carpentier, G. Auf, J. Y. Delattre // Frontiers in Bioscience. ‒ 2003. ‒ Vol. 8, N 5. ‒ P. 115–127. https://doi.org/10.2741/934Carpentier A. F., Auf G., Delattre J. Y. CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Frontiers in Bioscience, 2003, vol. 8, no. 5, pp. 115–127. https://doi.org/10.2741/934In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study / J. D. Brody [et al.] // J. of Clinical Oncology. ‒ 2010. ‒ Vol. 28, N 28. ‒ P. 4324‒4332. https://doi.org/10.1200/JCO.2010.28.9793Brody J. D., Ai W. Z., Czerwinski D. K., Torchia J. A., Levy M., Advani R. H., Kim Y. H., Hoppe R. T., Knox S. J., Shin L. K., Wapnir I., Tibshirani R. J., Levy R. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. Journal of Clinical Oncology, 2010, vol. 28, no. 28, pp. 4324‒4332. https://doi.org/10.1200/ JCO.2010.28.9793Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice / Y. Mizuno [et al.] // J. of Controlled Release. ‒ 2010. ‒ Vol. 141, N 2. ‒ P. 252–259. https://doi. org/10.1016/j.jconrel.2009.09.014Mizuno Y., Naoi T., Nishikawa M., Rattanakiat S., Hamaguchi N., Hashida M., Takakura Y. Simultaneous delivery of doxorubicin and immunostimulatory CpG motif to tumors using a plasmid DNA/doxorubicin complex in mice. Journal of Controlled Release, 2010, vol. 141, no. 2, pp. 252–259. https://doi.org/10.1016/j.jconrel.2009.09.014Promising targets for cancer immunotherapy: TLRs, RLRs, and STING-mediated innate immune pathways / K. Li [et al.] // Intern. J. of Molecular Sciences. ‒ 2017. ‒ Vol. 18, N 2. ‒ Art. 404. https://doi.org/10.3390/ijms18020404Li K., Qu S., Chen X., Wu Q., Shi M. Promising targets for cancer immunotherapy: TLRs, RLRs, and STING-mediated innate immune pathways. International Journal of Molecular Sciences, 2017, vol. 18, no. 2, art. 404. https://doi.org/ 10.3390/ijms18020404Zinchenko, A. I. Construction of plasmid enriched with immunostimulatory CpG motifs / A. I. Zinchenko, S. V. Kvach, A. S. Shchokolova // Eastern European Scientific J. ‒ 2014. – N 3. ‒ P. 10–13. https://doi.org/10.12851/EESJ201406C01ART02Zinchenko A. I., Kvach S. V., Shchokolova A. S. Construction of plasmid enriched with immunostimulatory CpG motifs. Eastern European Scientific Journal, 2014, no. 3, pp. 10–13. https://doi.org/10.12851/EESJ201406C01ART02Enzymatic synthesis of c-di-GMP using inclusion bodies of Thermotoga maritima full-length diguanylatecyclase / A. S. Korovashkina [et al.] // J. Biotechnol. ‒ 2012. ‒ Vol. 164, N 2. ‒ P. 276–280. https://doi.org/10.1016/j.jbiotec.2012.12.006Korovashkina A. S., Rymko A. N., Kvach S. V., Zinchenko A. I. Enzymatic synthesis of c-di-GMP using inclusion bodies of Thermotoga maritima full-length diguanylatecyclase. Journal of Biotechnology, 2012, vol. 164, no. 2, pp. 276–280. https://doi.org/10.1016/j.jbiotec.2012.12.006McNeel, D. G. Therapeutic cancer vaccines: how much closer are we? / D. G. McNeel // BioDrugs. ‒ 2017. ‒ Vol. 32, N 1. ‒ P. 1‒7. https://doi.org/10.1007/s40259-017-0257-yMcNeel D. G. Therapeutic cancer vaccines: how much closer are we? BioDrugs, 2017, vol. 32, no. 1, pp. 1‒7. https:// doi.org/10.1007/s40259-017-0257-yCancer immunogenomics: computational neoantigen identification and vaccine design / J. Hundal [et al.] // Cold Spring Harbor Symposia on Quantitative Biology. ‒ 2017. ‒ Vol. 81. ‒ P. 105‒111. https://doi.org/10.1101/sqb.2016.81.030726Hundal J., Miller C. A., Griffith M., Griffith O. L., Walker J., Kiwala S., Graubert A., McMichael J., Coffman A., Mardis E. R. Cancer immunogenomics: computational neoantigen identification and vaccine design. Cold Spring Harbor Symposia on Quantative Biology, 2017, vol. 81, pp. 105‒111. https://doi.org/10.1101/sqb.2016.81.030726

The authors declare that there are no conflicts of interest present.